OBJECTIVES: Real world data on secukinumab use among Thai patients with moderate to severe psoriasis are limited. This analysis aimed to describe baseline clinical characteristics and quality of life (QoL) of these patients.

METHODS: PROMPT is an observational prospective study conducted at 13 dermatology centers in Thailand between 2022 to 2025. Eligible adult patients with the first dose of secukinumab are enrolled and followed up for 2 years. In this interim analysis, clinical characteristics and QoL assessed by the Dermatology Life Quality Index (DLQI) and EQ-5D at baseline were analyzed.

RESULTS: Forty-two patients, with mean (SD) age of 45.7 (15.0) years, were included. Most of them were covered by the Civil Servant Medical Benefits Scheme (54.8%) or private insurance/self-pay (35.7%). Their means (SDs) of disease duration (years) and PASI score were 15.1 (12.3) and 13.1 (8.7). The most affected area was scalp (83.3%), followed by nail (64.3%), palmoplantar (38.1%), and genital (24.1%). Almost 62% of patients had at least one comorbidity, with metabolic diseases being the most common, and 5 patients had psoriatic arthritis. Most patients were previously treated with topical (83.3%) and systemic (66.7%) therapies, and naïve to biologics (92.9%). At baseline, most patients (81%) received a standard dose of secukinumab. The mean (SD) DLQI score was 14.4 (8.0), range 2-29. The most affected QoL domains were symptoms and feelings, leisure, and daily activities. The means (SDs) EQ-5D utility and visual analog scale scores were 0.8 (0.3) and 68.9 (19.9), with more problems in pain/discomfort and anxiety/depression.

CONCLUSIONS: Most patients had a long disease duration and were previously treated with several topical and systemic therapies, but psoriasis was still active and impacted their QoL. The distribution of patients in each health insurance scheme also highlighted the limited access to biologics treatment in Thailand.